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Introduction
The diastolic relaxation of the heart is an important 
phase of cardiac activity, which assures, by adequate fulfil 
of left ventricle cavity (LV), the feasibility of Frank Starling 
mechanism realizing (the length – force law) and of pump-
ing function.  But, on the other hand, the diastole is a vul-
nerable cardiac phase to the cardiovascular risk factors, but 
diastolic disorders are imposed as an early predictor of heart 
failure [1, 2]. Conceptually, the cardiac lusitrope function is 
dependent on different factors and conditions, like turnover 
of calcium into cardiomyocyte, indispensable for working 
of ionic pumps (first of all SERCA2a), as well as structural 
changes which develop at extracellular matrix and cardiac 
myocytes level [3, 4].
Among natural and synthetic factors with cardiotoxic ac-
tion, the anthracyclines (election drugs in neoplasm treat-
ment, e. g. doxorubicin) are positioned in a special format 
in the interdisciplinary plan of collaboration and mutual 
interest, oncology-cardiology. Cardiotoxicity of doxorubicin 
(Dx) may already progress to cumulative sub-therapeutic 
doses of the drug (<500 mg/m2), manifested by the onset 
and rapid progression of heart failure inherent to dilated car-
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Abstract
Background: The doxorubicin (Dx) cardiotoxicity is manifested by a marked heart failure evolution. The impact of Dx on lusitrop functions of the heart 
and the inherent diastolic disorders have a theoretical and practical value for the connection cardiology-oncology.
Material and methods: Dx cardiotoxicity was reproduced by its administration i/p in white rats in cumulative dose 16 mg/kg (Dx group n=9). Control 
group (n=9) received only physiological solution. The study was performed in vitro by using models of isolated heart perfusion in either isovolumic 
or exterior working regimens. The assayed indices of diastole functioning were: left ventricle (LV) end-diastolic pressure (LVEDP), diastolic stiffness, 
isovolumic relaxation velocity (-dP/dTmax) and protodiastolic pressure of LV (LVPDP).  
Results: The indices of diastolic disorders induced by Dx were elevation of LVEDP, diastolic stiffness and LVPDP in a range of 97-168% comparing to 
control as well as diminution of -dP/dTmax in the physiological pattern of hemodynamics. LVEDP increased more in conditions of calcium overloading 
or endothelin-1 (ET-1) action that are involved in pathogenesis of diastolic rigidity. Dx action led to decrease of myocardium resistance to ischemia-
reperfusion action resulting in the LVEDP elevation by 53% comparing to control.
Conclusions: 1. Diastolic disorders inherent to Dx cardiotoxicity are manifested by the increase of LVEDP and diastolic stiffness. 2. Diastolic disorders 
compromised the volume-pressure relationship of LV, the adaptation of the heart to effort with volume, being more pronounced during the action of 
calcium excess and ET-1.
Key words: doxorubicin cardiotoxicity, diastolic relaxation disorders.
Cite this article
Tacu L., Cobet V. Diastolic disorder inherent to doxorubicin cardiotoxicity. Mold Med J. 2021;64(4):23-28. https://doi.org/10.52418/moldovan-
med-j.64-4.21.04. 
Thus, there is a need to stop the administration of the 
drug, which reduces the chances of survival of the cancer 
patient, especially with leukemia and lymphoma. In this as-
pect, it is obvious that oncology and cardiology have a com-
mon task: the early detection of Dx cardiotoxicity and ap-
plication of measures to limit the characteristic myocardial 
injuries and dysfunction. 
The evaluation of Dx cardiotoxicity in terms of estima-
tion the nature of diastolic disorders is authentic and im-
portant from several points of view. First of all it is needed 
to highlight the pathogenetic mechanisms of triggering and 
exacerbation of heart failure. Secondly, the demarcation of 
functional predictors of Dx cardiotoxicity is important. And 
thirdly, it is important to determine the targets of pathoge-
netic treatment of heart failure.
The aim of the study was to evaluate in vitro the distur-
bances of diastolic relaxation characteristic for Dx cardio-
toxicity. 
Material and methods
Myocardial Dx disorder was reproduced in white rats 
by i/p administration of Dx (cumulative dose 16 mg/kg in 
2 weeks, 2 injections/per week at a dose of 4.0 mg/kg). The 
animals were sacrificed by euthanasia (sodium thiopental, 
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0.4 mg/kg) 10 days after the last anthracycline injection, as 
doxorubicin is a drug that, based on reduced clearance, ac-
cumulates in the body. This model of Dx-induced cardiotox-
icity has been used by other authors, aiming to highlight the 
link between the action of anthracycline and the inflamma-
tory response of the myocardium [5].
The isolated heart was perfused in isovolumic or work-
ing regime respectively according to the Langendorff and 
Neely-Rovetto method, the functional indices of LV being 
estimated by technical device for recording real-time param-
eters „Bio-Shel” (Australia) or the autograph Linearcorder 
MARK WR3101 (Germany) connected to the mechanical 
sensor. For estimation of diastolic relaxation peculiarities to-
gether with the performance of the LV pump function, were 
used the following functional indices:
- End-diastolic pressure (LVEDP),
- Protodiastolic pressure (LVPDP), 
- Maximum isovolumic relaxation rate (-dP/dTmax), 
- Diastolic stiffness,
- Aortic jet velocity, 
- Coronary flow,
- Cardiac output.
Functional reserves of diastole were estimated in various 
exercise stress tests: 
- Modification of filling pressure of the left atrium (ef-
fort with volume), 
- Increasing the filling volume of the LV cavity (vol-
ume-pressure relationship), 
- Increasing the retrograde perfusion pressure (coro-
nary pressure – diastolic compliance relationship),
- Stimulation of isolated heart with calcium and En-
dothelin 1 (ET-1),
- The ischemia-reperfusion impact.
The obtained data, exposed by the value M±m (mean 
and standard error), were compared and statistically ana-
lyzed, according to the t-Student criteria, with the control 
group (intact animals) or with indices attested before the ex-
ercise stress test. The error margin less than 5% was consid-
ered admissible and the deviation from the reference value 
was significant (p <0.05).
Results
Dx cardiotoxicity was imposed by marked impairment 
of diastolic relaxation, that already has been attested in the 
optimal perfusion regime of the isolated heart, when the fill-
ing pressure of the left atrium (LAFP) was 15 cmH2O, and 
the pressure in the aorta – 80 cmH2O (tab. 1).
One of the main important indices, estimating the feasi-
bility of diastolic relaxation, PTDVS, was increased by 168% 
in the group with Dx compared to the control one, which was 
associated with increased of more than 109% the value of 
diastolic stiffness. The diastolic disorder is based on distur-
bance of relaxation isovolumic phase of the heart, as key pa-
rameter of it, -dP/dT max, demonstrates a significant decline 
of 24.81%. Impaired diastolic relaxation compromises systo-
lic contraction due to the inefficiency of the Frank-Starling 
mechanism. Thus, the protodiastolic pressure, which means 
LV pressure at the end of systole, is elevated by 97% in the 
group with Dx.
table 1.  Indices of diastolic relaxation of the isolated 















Diastolic stiffness of 
LV,  mm Hg/ml








The manifestations of the heart lusitrop function distur-
bances at administration of Dx can be determined by esti-
mating the diastolic stiffness of the LV, which was clearly 
increased by 109% compared to the control index. Diastolic 
stiffness shows the ratio between rate of increasing LV pres-
sure during diastolic filling to the stroke volume or systolic 
volume. As a consequence, the parameters of the LV pump 
function were significantly reduced compared to the control 
group (tab. 2).
The aortic jet decreased by 40.47%, which determined 
the decreased cardiac output by 36.9%, caused by decreased 
coronary flow by 31.65%. 
Manifestations of impaired diastolic relaxation in the 
group with Dx become more pronounced in the hemody-
namic effort tests, with calcium, ET-1, as well as in the im-
pact of ischemia-reperfusion.
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In the exercise effort test with minimal filling pressure 
of the left atrium (LAFP) (5 cm H2O) the depreciation of 
the index -dP/dT max compared to the control prototype in-
creased from 24.81% to 32.77% (tab. 3).
Compared to the index attested in the perfusion of the 
isolated heart in physiological comfort regime, its value in-
creased in both groups, but the enhancement was different: 
in the control group -dP/dT max was increased by 19% and 
in the group with Dx – only by 7 %. In conditions of decreas-
ing the venous return to the heart, the phase of isovolumic 
relaxation of the heart has a decisive significance in order to 
ensure as much as possible the filling of the left ventricular 
cavity based on developing the adequate pressure gradient.
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table 3.  Value of functional indices of the cord isolated 






Aortic jet velocity, ml/min 5.7±0.3 1.6±0.1
-71.93% vs control
<0.001










-dP/dT max, mm Hg/sec 7966±188 5356±149
-32.77% vs control
<0.05
The pumping function of LV appreciated after the aortic 
jet had a decline of 87.5% (in the control group – 73.5%) 
reaching an average value of 1.6 ml/min that is 71.93% lower 
than control index (5.7±0.3 ml/min). The end-diastolic pres-
sure decreased intelligibly in both groups, but its value re-
maining significantly higher in the group with Dx, the dif-
ference being 78%. The protodiastolic pressure decreased 
simultaneously with the decreasing of filling pressure of the 
left atrium, the smaller rebound being characteristic for Dx 
cardiotoxicity (68.83 vs 71.8%), which indicates a weaker 
systole compared to the control group.
In the sample with maximum LAFP (25 cmH2O) the LV 
filling is facilitated due to an artificial gradient installed be-
tween the left atrium and the left ventricle. However, the re-
duced diastolic compliance of the myocardium in the group 
with Dx conditioned a higher elevation of LVEDP compared 
to the control pattern: 5.6 vs 2.1 mm Hg (tab. 4).
As a consequence, the value of LVEDP in this volume 
stress test became 184% higher than the index in the control 
group.
The reduced diastolic compliance was manifested by in-
creasing the value of diastolic stiffness by 129%, this being 
higher than the enhancement attested to the perfusion of 
isolated heart in physiological regime (109.73%). Limiting 
the filling of the LV cavity due to increased diastolic stiffness 
of the myocardium led to lower values of the pump function 
indices. The aortic jet, for example, was found to be reduced 
by 42.6%, and stroke volume – by 25%.
table 4. Values of functional indices of the heart isolated 
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Evidence of impaired diastolic relaxation at Dx admin-
istration was also confirmed on the retrograde perfusion 
model without recirculation of the isolated heart (Langedorff 
method, to unify the initial values of LVEDP) in the condi-
tions of increased filling (tab. 5).
The impact of the gradual increasing of LV filling vol-
ume on LVEDP hemodynamics is different between batches, 
taking into account that initial volume was similar (0.2 ml) 
and LVEDP was calibrated at 14 mm Hg level. In the con-
trol group, the elevation of LVEDP, in conditions of increas-
ing LV volume from 0.2 up to 0.4 ml, was found in a range 
of 7-51%. The cardiotoxicity of doxorubicin increased the 
LVEDP to 95.8%, which led to a significant 30% lag of the 
index at the end of the test: 27.4±1.6 vs 21.2±1.2 mm Hg.
Due to a higher elevation of the end-diastolic pressure 
of LV in the group with Dx, a more conclusive depreciation 
of coronary flow was attested. Compared to the control pro-
totype, the decline of coronary flow in conditions of dou-
bling the filling volume of LV was with 46% higher (45.33 
vs 31.21%), and the final rebound of absolute value of the 
CF (coronary flow) was 21.65% (7.6±0.5 vs 9.7±0.3 ml/min).





Left ventricular filling volume of isovolumic heart
0.25 ml 0.30 ml 0.35 ml 0.40 ml







































Note: LVFV – left ventricular filling volume; CF – coronary flow; +/-% – relative deviations of the indices compared to their initial value; p – the significance 
of the discrepancy versus the respective index; * – p<0.05 versus initial value; 
** – p <0.01 versus initial value.
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An important intrinsic factor that influences the func-
tionality of diastolic relaxation is the pressure of the coro-
nary perfusion, which on the retrograde perfusion model of 
the isolated isovolumic heart is dependent on the perfusion 
volume of the coronary system. In this context, there was es-
timated the hemodynamics of LVEDP modification in con-
ditions of increasing the pressure in the aortic estuary from 
80 up to 120 cmH2O (tab. 6). 
table 6.  the LVEDP hemodynamics in conditions of 
increased coronary pressure of the isolated isovolumic 
heart
Groups





14 mm Hg 15.6±1.2 16.3±1.4
Dx (n=9) 14 mm Hg 18.3±1.3




It should be mentioned that LVEDP was measured at 
the level of the initial or basal aortic pressure (80 cmH2O) 
equal in both batches with 14 mmHg, by the latex balloon 
placed in the cavity of the left ventricle. The progression of 
coronary hypertension has led in both groups to a natural ef-
fect – the elevation of LVEDP. But, in the group with Dx, the 
increase of the end-diastolic pressure of LV was much more 
pronounced. At the level of aortic pressure of 100 cmH2O, 
the LVEDP value increased by 31% compared to the control 
increment of 12%. At the maximum level of coronary pres-
sure (120 cmH2O) the enhancement of LVEDP was 42%, 
which is 147% higher than the control increment equal to 
17%. As a consequence at both levels of coronary blood pres-
sure LVEDP in doxorubicin disorder of the heart was signifi-
cantly higher compared to the control pattern by 18% and 
22%, respectively.
The lusitrop function of the heart is influenced by sev-
eral neuroendocrine factors (e.g., ET-1, catecholamines, 
angiotensin II), which normally had a positive inotropic ef-
fect due to the increased calcium concentration in the sar-
coplasm. In order to estimate the character of the diastole 
change under the action of ET-1 and excess calcium, was 
appreciated the basal value, as well as the value of LVEDP, 
as well as the index value at the peak of stimulation of the 
isolated heart perfused in working regime (tab. 7). 
table 7.  Modification of LVEDP to the action of Et-1 
and excess of calcium
Groups ET-1(10-7 М) Calcium (3.0 mM)













<0.001 <0.001 <0.001 <0.001
The action of both factors on the isolated heart was im-
posed by elevating LVEDP, both in the control group and in 
the group with Dx, the more conclusive effect being charac-
teristic for the excess of calcium. Remarkably, that enhance-
ment of LVEDP was significantly higher in the doxorubicin 
group. Thus, under the action of ET-1 the rate of LVEDP el-
evation was imposed by the ratio of 42 vs 25%, and under 
the action of calcium excess (increasing the concentration of 
Ca2+ in perfusion from 2.5 up to 3.0 mM) – 71 vs 44%.
As a result of these quantitatively distinct changes, the 
cardiotoxicity of Dx was imposed by a clearly higher stimu-
lation of LVEDP than the control, by 191% under the action 
of ET-1 and by 208% under the action of calcium excess. 
These differences are obviously larger compared to the ini-
tially estimated patterns, so till stimulation of isolated heart.
A cardinal factor that detrimentally influences the di-
astolic functionality is myocardial ATP deficiency resulting 
in the progressive accumulation of calcium in the cardio-
myocyte during diastole relaxation due to the incompetence 
of ionic pumps, primarily of the ATP-ase of sarcoplasmic 
reticulum (SERCA2a). This phenomenon affects the disso-
ciation of actin-myosin complex and led to development of 
diastolic stiffness, which to a severe degree is noted as di-
astolic contracture. Because myocardial ischemia represents 
a major condition of impaired bioenergy synthesis and cal-
cium metabolism, the severity of its impact on the LVEDP 
hemodynamics and capacity of lusitrope to restore function 
during reperfusion was estimated (tab. 8).
It should be mentioned that in both groups the basal 
value of LVEDP, until the action of ischemia, was installed 
at equal levels: 14 ± 0.1 mm Hg. According to the estimated 
hemodynamics of LVEDP, cardiac doxorubicin disorder was 
manifested by a considerable reduction in myocardial toler-
ance to ischemic impact. Thus, LVEDP has increased during 
ischemia period of 30 min to the average value of 63.7 mm 
table 8.  the LVEDP hemodynamics during ischemia and isovolumic 
isolated heart reperfusion
Groups
Ischemia (min) Reperfusion (min)
5 10 20 30 5 10 30 45
Control (n=9) 16.3±0.8 27.2±1.7 36.2±1.9 41.7±2.3 36.3±2.5 27.9±2.3 20.7±1.8 14.9±1.1
Dx  (n=9) 21.5±1.4 38.8±2.1 55.6±3.6 63.7±4.4 58.2±4.3 46.5±3.3 30.6±2.5 22.8±1.4
p <0.05 <0.05 <0.01 <0.01 <0.05 <0.05 <0.05 <0.01
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Hg, and in the control group the index reached 41.7 ± 2.3 
mm Hg, the final difference being 53%. Moreover, the qual-
ity of LVEDP recovery in the Dx group was much poorer. If 
in the control group the index at 45 minutes of reperfusion 
practically reached the basal level (14.9±1.1 mm Hg), then 
in the group with Dx it remains clearly higher (22.8±1.4 mm 
Hg), the difference remaining at the levels of the final period 
of ischemia, 53%.
Discussion
The researchers in vitro on isovolumic isolated and work-
ing heart perfusion models (Langedorff and Neely-Rovetto 
methods) have demonstrated that the cardiotoxicity of 
doxorubicin is imposed by significantly affecting diastolic 
relaxation. Already in physiological hemodynamic regime, 
LVEDP values and diastolic stiffness were considerably in-
creased more than double (109-168%) compared to the con-
trol group indices. Increased diastolic stiffness was associ-
ated with a significant 24.8% reduction in isovolumic relaxa-
tion rate (-dP/dTmax).
The diastolic disorder in the Dx group is one of the main 
causes of impaired pump function of the left ventricle, man-
ifested by a 36.9% decline in cardiac output, as worsening 
lusitrop function indices in volume effort tests were accom-
panied by increased rebound of the pump function parame-
ters. In conditions of reducing the venous return to the heart 
to the minimal value (5 cmH2O) the difference of the - dP/
dTmax index compared to the control increased by 32%, and 
the aortic jet rebound increased by 78%. At maximum LV 
filling the increased diastolic stiffness of the myocardium led 
to elevation of LVEDP by about 2.3 times compared to the 
control, and the hemodynamics of the volume-pressure re-
lationship gradually reproduced on the isovolumic isolated 
heart perfusion model has the pattern of an upward curve 
compared to the control prototype. The increased diastolic 
stiffness is conceptually viewed as an intrinsic factor of in-
creasing myocardial mechanical stress that limits coronary 
perfusion especially in the subendocardial layer [6, 7].
In this study, the doubling of the filling volume of the 
isolated isovolumic heart was manifested in the Dx disorder 
of the myocardium by decreasing the coronary flow more 
accentuated compared to the control pattern by 46%, which 
correlated with an end-diastolic pressure of LV well above 
the control level. Impairment of coronary perfusion is an im-
portant pathogenetic factor in the disorder of the heart’s ad-
aptation to overload with volume and resistance, especially 
when myocardial dysfunction is directly related to impaired 
endothelium-dependent vascular relaxation, which can be 
compensated by the feasibility of the Vanhoutte phenom-
enon based on repolarization mechanism of vascular muscle 
media [8].
It should be mentioned that in the interface of depend-
ence the coronary perfusion on the diastolic myocardial ri-
gidity, it is also valid the inverse relation: the coronary flow 
influences the diastolic relaxation. In the presented research 
this aspect was confirmed. Thus, the increase of the retro-
grade perfusion pressure of the isolated isovolumic heart by 
50% led to the elevation of LVEDP, while in the group with 
Dx the index increase was 147% higher compared to the 
control increase.
One of the mechanisms highlighted in this study on the 
impairment of diastolic relaxation in the repeated adminis-
tration of Dx is the incompetence of the control system of 
calcium ion turnover in the cardiomyocyte during the sys-
tole-diastole cycle. The increasing calcium concentration in 
perfusion by 0.5 mM led to a more conclusive elevation of 
the LVEDP value by 62% compared to the rate of increase of 
the control index, which indicates the dysfunction of the cal-
cium pumps, first of all the ATP-ases of the sarcoplasmic re-
ticulum (SERCA2a) together with myocardial energy deficit. 
A similar phenomenon was observed in the isolated heart 
stimulation with ET-1, which increases the influx of calcium 
following the activation of ETA receptors. The diastolic dis-
order at the peak of stimulation of the isolated heart per-
fused in working regime with ET-1 was imposed by negative 
inotropic effect, manifested by decreased LV systolic pres-
sure and cardiac output, evidences associated with a more 
pronounced elevation of LVEDP [9].
The role of excess calcium in diastolic disorder under 
the cardiotoxic impact of Dx was confirmed in a previous 
study, in which the chronic or acute action of taurine (natu-
ral modulator of calcium metabolism and bioenergetics) sig-
nificantly improved the lusitrop function of the heart as well 
as parameters of LV pump function [10]. The similar results 
were obtained by other authors, who demonstrated the ben-
efit of taurine administered for 14 days in the model of Dx 
myocardial disorder in rats on echocardiographic indicators, 
the first on the reduction of LV end-diastolic volume as a 
true sign of diastole improvement [11]. Taurine also has a 
remarkable antioxidant effect, and Dx cardiotoxicity, on the 
contrary, is marked by a prooxidant effect and, respectively, 
the activation of oxidative stress [12].
The diastolic disorder in the group with Dx was charac-
terized by a more pronounced ischemic contracture vs con-
trol. Moreover, during the reperfusion period, the restoration 
of the lusitrop function of the heart in the group with Dx was 
frankly compromised, so that LVEDP remains 53% above 
the control index. The pathophysiological substrate of the 
ischemia-reperfusion impact is determined by the rapid en-
ergetic decline, the accumulation of calcium in the heart cells, 
as well as the excess of oxygen free radicals. These pathoge-
netic mechanisms are the main elements of the pathophysio-
logical interface regarding the disturbance of diastolic relaxa-
tion and the evolution of doxorubicin heart failure.
The impairment of diastole under the cardiotoxic action 
of Dx may also be related to the detrimental action of an-
thracycline on the extracellular matrix. In the context of the 
latest literature data is to be highlighted the effect of Dx to 
induce heart cell death by apoptosis, pyroptosis and ferrop-
tosis [13].
Pyroptosis is triggered by the inflammatory response of 
the myocardium induced by Dx, and the increased expres-
sion of proinflammatory cytokines and chemokines remains 
during the cessation of its action. The inflammatory respons-
es together with oxygen free radicals influence the extracel-
lular matrix by activating metalloproteinases, fibroblasts and 
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interstitial macrophages. As a result, the extracellular matrix 
increases due to fibrillar collagen type I and III, as well as de-
graded collagen. These changes in the interstitium obviously 
decrease the diastolic compliance of the myocardium caused 
by reducing cardiomyocyte counts.
Ferroptosis under the action of Dx is mediated by the ac-
cumulation of iron ions in the mitochondria of the cardio-
myocyte, which has a negative effect on the synthesis control 
of ATP molecules and oxygen free radicals, which justifies 
this phenomenon as a mechanism responsible for Dx car-
diotoxicity [14], as well as a heart protection target in cancer 
patients exposed to the anthracyclines action [15].
An important aspect of the clinical applicability of the 
data obtained in cardiology-oncology is the proof of the key 
role of isovolumic diastolic relaxation disorder of the heart 
in disturbance of the LV pump function, and on the other 
hand elucidating the mechanism of early growth of the Tei 
index in cardiac patients exposed to cardiotoxic effect of 
anthracyclines [16]. Therefore, the increase of the Tei index 
values as an early predictor of cardiac dysfunction under the 
action of Dx is based primarily on increasing the time of iso-
volumic relaxation of the heart resulting in reduced ejection 
time of the left ventricle.
Conclusions
1. Impairment of diastolic relaxation inherent to Dx car-
diotoxicity is manifested mainly by significant increase of 
LVEDP and diastolic stiffness in association with reducing 
the isovolumic diastolic relaxation velocity. 
2. Diastolic disorders compromise the volume-pressure 
relationship of LV, the adaptation of the heart to effort with 
volume and become more pronounced during the action of 
calcium excess and ET-1.
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